Icelander chemical industry news

19 November 2025
Merck's KEYTRUDA® Subcutaneous Form Approved by European Commission
KEYTRUDA SC, a subcutaneous immune checkpoint inhibitor, is approved in Europe for faster administration across all adult indications.
18 November 2025
EU Imposes Safeguard Measures on Ferroalloy Imports; Impact on Elkem
The EU enacts tariff rate quotas on ferroalloy imports, effective Nov 2025 for three years, excluding silicon metal. Elkem anticipates sales shifts and potential price increases.
23 October 2025
Elkem Q3 2025: Strong Operations and Cost Improvements Boost Results
EBITDA fell 33% YoY due to low sales prices. Silicones division under review for sale. EU and US trade measures may impact future performance.
20 October 2025
Elkem Reduces Ferrosilicon Output in Norway and Iceland
Production cut due to weak European market and EU import investigation. Temporary layoffs possible. Aims to lower inventory and stabilize market.
19 September 2025
Merck's ENFLONSIA™ Recommended by EU CHMP for RSV Prevention in Infants
ENFLONSIA™ awaits EU approval for infant RSV prevention, offering a single-dose option for all weights. Backed by Phase 2b/3 and Phase 3 trials, decision expected by year-end.
19 September 2025
Merck Gains EU CHMP Support for KEYTRUDA SC and New Head and Neck Cancer Use
CHMP backs KEYTRUDA SC for all EU adult indications and a new use in LA-HNSCC. Awaiting European Commission's final decision.

How does the Icelander chemical industry perform?

Find out with chemXplore Analytics